FBXO5 and breast carcinoma: Notably, FBXO5 was reported to promote the proliferation of breast cancer cells through PI3K/Akt signaling pathway, leading to a grim prognosis, whereas PI3K inhibitor LY294002 repressed FBXO5 expression and cell proliferative capacity (11).